Abstract 243P
Background
Target sequencing of epithelial ovarian cancer (EOC) has been widely used in clinical to detect the status of BRCA1/2 and genes in homologous recombination repair (HRR) pathway.
Methods
In a prospective study, unselected 215 EOC patients underwent germline and somatic testing with a 25-gene panel, of which 147 patients received target sequencing of 508 genes in OseqT panel. The sensitivity to platinum-based chemotherapy, OS and PFS were explored in various mutation categories.
Results
In 215 patients. 57 (26.51%) patients carried BRCA1 (46, 21.4%) or BRCA2 (14, 6.5%) pathogenic or likely pathogenic variants,3 of them carried both BRCA1 and BRCA2 variants. BRCA1/2 pathogenic carriers had significantly superior PFS and OS than non-mutated group. Deleterious mutation in HRR and MMR related genes can be found in 70 (32.6%) and 3 (1.4%) patients. Among 147 patients using OseqT panel for sequencing, 103 (70.1%), 15 (10.2%), 8 (5.4%), and 15 (10.2%) patients carried mutations of TP53, BRCA1, BRCA2, and PIK3CA mutations. There are also 2, 2 and 3 patients carrying mutations of p.E542K, p.E545K and p.H1047R mutations in PIK3CA , respectively. Mutations in ARID1A (11 patients, 7.4%), NF1 (7, 4.7%) and PTEN (6, 4.1%) can also be detected. In 118 patients received MSI testing, 22 (18.6%) of them are microsatellite instability (MSI)-low.
Conclusions
While BRCA1/2 and HRR related gene is still the most important target for gene test of EOC patient. The high prevalence of other cancer related gene such as PIK3CA cannot be overlooked. Large panel containing more cancer related genes may provide extra suggestions for doctors.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
61P - Clinical implication of BRCA mutation in breast cancer with central nervous system metastasis
Presenter: Jwa Hoon Kim
Session: e-Poster Display Session
62P - IGF axis in breast cancer recurrence and metastasis
Presenter: Hajara Akhter
Session: e-Poster Display Session
63P - Butterfly pea (<italic>Clitoria ternatea</italic> Linn.) flower extract prevents MCF-7 HER2-positive breast cancer cell metastasis in-vitro
Presenter: Azzahra Asysyifa
Session: e-Poster Display Session
64P - Pre-treatment absolute white blood cell profile count as metastatic predictive factors in invasive ductal carcinoma breast cancer
Presenter: Wikania I Gede
Session: e-Poster Display Session
65P - The new mouse anti-nNav1.5 monoclonal antibody
Presenter: Nur Aishah Sharudin
Session: e-Poster Display Session
66P - The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer
Presenter: Vladimir Alifanov
Session: e-Poster Display Session
73P - Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: e-Poster Display Session
74P - Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
Presenter: Yoshiyuki Suehara
Session: e-Poster Display Session
75P - The evaluation of selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Presenter: Leo Yamada
Session: e-Poster Display Session
76P - Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Presenter: Vivek Raju
Session: e-Poster Display Session